Christopher Bowles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher Bowles has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- María Monteagudo-Vela
Cardiothoracic Surgery Department, Hospital Universitario de la Princesa, Madrid, Spain
3 shared publications Andrew Morley‐Smith
Harefield Hospital, Guy’s and St Thomas’ NHS Foundation Trust
2 shared publications- Binu Raj
Transplantation, Harefield Hospital, Royal Brompton and Harefield as part of Guy’s and St Thomas NHS Trust, London, UK
2 shared publications Fernando Riesgo Gil
Harefield Hospital, Guy’s and St Thomas’ NHS Foundation Trust
2 shared publications- Guglielmo Gallone
Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Medical Sciences, University of Turin, Turin, Italy
2 shared publications - Javier Ibero
Department of Cardiology and Cardiac Surgery, Clínica Universidad de Navarra, Spain
2 shared publications
Latest Publications
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e041475
Validation of the Hemodynamic Classification System for Hemodynamic‐Related Events in Patients With Durable Left Ventricular Assist Devices
Background: Durable left ventricular assist device (dLVAD) physiology predisposes to right heart failure (RHF) and aortic insufficiency (AI), recently labeled hemodynamic‐related events (HDREs). We sought to validate the recently proposed dLVAD Hemodynamic Classification System for HDREs. Methods: RHF and AI HDREs were adjudicated, staged, and phenotyped on the basis of the Hemodynamic Classification System assessed at 6 months after dLVAD implantation. The primary outcome was a composite of HF hospitalization or cardiovascular death between 6 and 24 months after dLVAD implantation. Results: Among 183 qualifying consecutive patients with 6‐month assessments, RHF HDRE was adjudicated in all cases and AI HDRE in 161 (88.0%). Overall, 53 (29.0%) patients developed an RHF HDRE and 26 (16.0%) an AI HDRE (phenotypes: 39 isolated RHF, 15 isolated AI, 11 combined RHF–AI, 3 not adjudicated). At pre‐dLVAD assessment, age and pulmonary artery pulsatility index were independently associated with RHF HDRE and pre‐dLVAD AI and systolic pulmonary artery pressure with AI HDRE. RHF HDRE (adjusted hazard ratio [HR], 2.69 [95% CI, 1.14–6.34]; P =0.024), AI HDRE (adjusted HR, 4.21 [95% CI, 1.70–10.40]; P =0.002), and HDRE phenotypes (isolated RHF/AI HDRE versus no HDRE: adjusted HR, 2.80 [95% CI, 1.03–7.62]; P =0.044; combined RHF/AI HDRE versus no HDRE: adjusted HR, 4.53 [95% CI, 1.33–15.35]; P =0.015) were associated with the primary outcome. A graded increase in primary outcome was observed with increasing RHF and AI stages. Conclusions: We validated the dLVAD Hemodynamic Classification System for HDREs as a valuable tool to identify pathophysiological and clinical clusters of patients, linking it with significant prognostic implications. Its adoption may pave the way for targeted strategies aimed at mitigating HDREs and enhancing the long‐term success of dLVAD support.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e041475
Open AccessValidation of the Hemodynamic Classification System for Hemodynamic‐Related Events in Patients With Durable Left Ventricular Assist Devices
Background: Durable left ventricular assist device (dLVAD) physiology predisposes to right heart failure (RHF) and aortic insufficiency (AI), recently labeled hemodynamic‐related events (HDREs). We sought to validate the recently proposed dLVAD Hemodynamic Classification System for HDREs. Methods: RHF and AI HDREs were adjudicated, staged, and phenotyped on the basis of the Hemodynamic Classification System assessed at 6 months after dLVAD implantation. The primary outcome was a composite of HF hospitalization or cardiovascular death between 6 and 24 months after dLVAD implantation. Results: Among 183 qualifying consecutive patients with 6‐month assessments, RHF HDRE was adjudicated in all cases and AI HDRE in 161 (88.0%). Overall, 53 (29.0%) patients developed an RHF HDRE and 26 (16.0%) an AI HDRE (phenotypes: 39 isolated RHF, 15 isolated AI, 11 combined RHF–AI, 3 not adjudicated). At pre‐dLVAD assessment, age and pulmonary artery pulsatility index were independently associated with RHF HDRE and pre‐dLVAD AI and systolic pulmonary artery pressure with AI HDRE. RHF HDRE (adjusted hazard ratio [HR], 2.69 [95% CI, 1.14–6.34]; P =0.024), AI HDRE (adjusted HR, 4.21 [95% CI, 1.70–10.40]; P =0.002), and HDRE phenotypes (isolated RHF/AI HDRE versus no HDRE: adjusted HR, 2.80 [95% CI, 1.03–7.62]; P =0.044; combined RHF/AI HDRE versus no HDRE: adjusted HR, 4.53 [95% CI, 1.33–15.35]; P =0.015) were associated with the primary outcome. A graded increase in primary outcome was observed with increasing RHF and AI stages. Conclusions: We validated the dLVAD Hemodynamic Classification System for HDREs as a valuable tool to identify pathophysiological and clinical clusters of patients, linking it with significant prognostic implications. Its adoption may pave the way for targeted strategies aimed at mitigating HDREs and enhancing the long‐term success of dLVAD support.
- Open Access
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e032617
Association of Renin‐Angiotensin‐Aldosterone System Inhibitors With Clinical Outcomes, Hemodynamics, and Myocardial Remodeling Among Patients With Advanced Heart Failure on Left Ventricular Assist Device Support
Background: We evaluated the potential benefits of renin‐angiotensin‐aldosterone system inhibitors (RAASi) in patients with left ventricular assist device support. Methods and Results: A total of 165 consecutive patients undergoing left ventricular assist device implant and alive at 6‐month on support were studied. RAASi status after 6‐month visit along with clinical reasons for nonprescription/uptitration were retrospectively assessed. The primary outcome was a composite of heart failure hospitalization or cardiovascular death between 6 and 24 months after left ventricular assist device implant. Remodeling and hemodynamic outcomes were explored by studying the association of RAASi new prescription/uptitration versus unmodified therapy at 6‐month visit with the change in echocardiographic parameters and hemodynamics between 6 and 18 months. After the 6‐month visit, 76% of patients were on RAASi. Patients' characteristics among those receiving and not receiving RAASi were mostly similar. Of 85 (52%) patients without RAASi new prescription/uptitration at 6‐month visit, 62% had no apparent clinical reason. RAASi were independently associated with the primary outcome (adjusted hazard ratio, 0.31 [95% CI, 0.16–0.69]). The baseline rates of optimal echocardiographic profile (neutral interventricular septum, mitral regurgitation less than mild, and aortic valve opening) and hemodynamic profile (cardiac index ≥2.2 L/min per m 2 , wedge pressure P =0.032) and trends for higher rates of optimal echocardiographic profile (39.6% versus 22.9%; P =0.055) compared with patients with 6‐month unmodified therapy. Optimal 18‐month hemodynamic and echocardiographic profiles were associated with the primary outcome (log‐rank=0.022 and log‐rank=0.035, respectively). Conclusions: RAASi are associated with improved outcomes and improved hemodynamics among mechanically unloaded patients.
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e032617
Open AccessAssociation of Renin‐Angiotensin‐Aldosterone System Inhibitors With Clinical Outcomes, Hemodynamics, and Myocardial Remodeling Among Patients With Advanced Heart Failure on Left Ventricular Assist Device Support
Background: We evaluated the potential benefits of renin‐angiotensin‐aldosterone system inhibitors (RAASi) in patients with left ventricular assist device support. Methods and Results: A total of 165 consecutive patients undergoing left ventricular assist device implant and alive at 6‐month on support were studied. RAASi status after 6‐month visit along with clinical reasons for nonprescription/uptitration were retrospectively assessed. The primary outcome was a composite of heart failure hospitalization or cardiovascular death between 6 and 24 months after left ventricular assist device implant. Remodeling and hemodynamic outcomes were explored by studying the association of RAASi new prescription/uptitration versus unmodified therapy at 6‐month visit with the change in echocardiographic parameters and hemodynamics between 6 and 18 months. After the 6‐month visit, 76% of patients were on RAASi. Patients' characteristics among those receiving and not receiving RAASi were mostly similar. Of 85 (52%) patients without RAASi new prescription/uptitration at 6‐month visit, 62% had no apparent clinical reason. RAASi were independently associated with the primary outcome (adjusted hazard ratio, 0.31 [95% CI, 0.16–0.69]). The baseline rates of optimal echocardiographic profile (neutral interventricular septum, mitral regurgitation less than mild, and aortic valve opening) and hemodynamic profile (cardiac index ≥2.2 L/min per m 2 , wedge pressure P =0.032) and trends for higher rates of optimal echocardiographic profile (39.6% versus 22.9%; P =0.055) compared with patients with 6‐month unmodified therapy. Optimal 18‐month hemodynamic and echocardiographic profiles were associated with the primary outcome (log‐rank=0.022 and log‐rank=0.035, respectively). Conclusions: RAASi are associated with improved outcomes and improved hemodynamics among mechanically unloaded patients.
- Open Access
- 24 November 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (2) , 322-325
Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
Although the activated partial thromboplastin time (aPTT) has historically been the method of choice for anticoagulation monitoring in patients undergoing mechanical circulatory support with intravenous unfractionated heparin, it is being progressively superseded by the anti-factor Xa (anti-Xa) method. A retrospective single-arm, single-centre analysis of 20 patients who underwent total artificial heart implantation entailed simultaneous determinations of aPTT and anti-Xa. Agreement between these parameters was assessed using the Bland–Altman method. Despite a positive correlation between aPTT and anti-Xa, normal target ranges were poorly aligned: from 5th to 30th postoperative day, for anti-Xa values of 0.2 and 0.4 U/ml corresponding aPTT values were 52.1 and 65.2 s, 7.9 and 14.8 lower than predicted values, respectively. This was not associated with thromboembolic sequalae. It was not possible to demonstrate a significant relationship between the predictor variables (postoperative day; white blood cell count; C-reactive protein concentration; alanine transaminase and alkaline phosphatase level; bilirubin; haemoglobin; albumin and total protein concentration) and the agreement between aPTT and anti-Xa levels. In summary, when anti-Xa levels were used to guide anticoagulation therapy, corresponding aPTT levels were low with respect to target range. Methodology applied in this study is generalizable to other forms of mechanical circulatory support.
- 24 November 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (2) , 322-325
Open AccessAnticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
Although the activated partial thromboplastin time (aPTT) has historically been the method of choice for anticoagulation monitoring in patients undergoing mechanical circulatory support with intravenous unfractionated heparin, it is being progressively superseded by the anti-factor Xa (anti-Xa) method. A retrospective single-arm, single-centre analysis of 20 patients who underwent total artificial heart implantation entailed simultaneous determinations of aPTT and anti-Xa. Agreement between these parameters was assessed using the Bland–Altman method. Despite a positive correlation between aPTT and anti-Xa, normal target ranges were poorly aligned: from 5th to 30th postoperative day, for anti-Xa values of 0.2 and 0.4 U/ml corresponding aPTT values were 52.1 and 65.2 s, 7.9 and 14.8 lower than predicted values, respectively. This was not associated with thromboembolic sequalae. It was not possible to demonstrate a significant relationship between the predictor variables (postoperative day; white blood cell count; C-reactive protein concentration; alanine transaminase and alkaline phosphatase level; bilirubin; haemoglobin; albumin and total protein concentration) and the agreement between aPTT and anti-Xa levels. In summary, when anti-Xa levels were used to guide anticoagulation therapy, corresponding aPTT levels were low with respect to target range. Methodology applied in this study is generalizable to other forms of mechanical circulatory support.